Last reviewed · How we verify

efalizumab plus acitretin — Competitive Intelligence Brief

efalizumab plus acitretin (efalizumab plus acitretin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + retinoid combination. Area: Dermatology/Immunology.

marketed Monoclonal antibody + retinoid combination CD11a (LFA-1) + retinoid X receptor (RXR) / retinoid acid receptor (RAR) Dermatology/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

efalizumab plus acitretin (efalizumab plus acitretin) — Universita di Verona. Efalizumab blocks T-cell activation and migration to skin while acitretin reduces keratinocyte proliferation and differentiation, together providing dual immunological and differentiation-based control of psoriasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
efalizumab plus acitretin TARGET efalizumab plus acitretin Universita di Verona marketed Monoclonal antibody + retinoid combination CD11a (LFA-1) + retinoid X receptor (RXR) / retinoid acid receptor (RAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + retinoid combination class)

  1. Universita di Verona · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). efalizumab plus acitretin — Competitive Intelligence Brief. https://druglandscape.com/ci/efalizumab-plus-acitretin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: